INTRODUCTION
With complex viruses such as herpes simplex virus (HSV), the understanding of the role of individual proteins in virus-host interaction events is still in its infancy. It is often assumed that seven or more major HSV glycoproteins found in the viral envelope as well as at the surface of infected cells primarily influence the outcome of infection. Currently, using in vitro approaches, unique functions of some of these individual glycoproteins have been revealed (Cai et al., 1988; Friedman et al., 1984; Johnson et al., 1988; Gompels & Minson, 1986) but the full nature of their functional role in vivo needs to be firmly established. It will be particularly important to elucidate the contribution of these individual glycoproteins to the induction of immunity since such knowledge is essential for the optimal design of vaccines. In the case of HSV infections, we lack acceptable vaccines to prevent infection and also require reagents that could be administered to infected individuals to reduce the frequency and severity of their recrudescent episodes. The production of recombinant viruses with cloned individual genes is one of the potentially more useful ways of assessing the immunobiological function of single HSV proteins, especially as it relates to their role in immunity. To date, several HSV glycoprotein genes have been incorporated into vaccinia virus vectors and shown to induce some aspects of HSV-l-specific immunity when used to vaccinate animals (gB, Cantin et al., 1987; gD, Cremer et al., 1985; gC, J. P. Weir, personal communication; gG, Sullivan & Smith, 1987; gI, Sullivan & Smith, 1988) . In this report, we describe the use of a recombinant vaccinia virus that expresses the B gene of HSV-1 strain F (Cantin et al., 1987) and demonstrate that immunization with this vector induces several aspects of an HSV-l-specific protective response. However, a detailed analysis of the responses induced revealed an incomplete array of antiviral mechanisms, in particular a failure to induce an HSV-l-specific cytotoxic T lymphocyte (CTL) response. This failure to induce an adequate repertoire of immune effectors may account for the failure of vaccinated mice to control a localized primary HSV-1 infection, an infection chosen to mimic the classical disease seen in man (Hill et al., 1975) . The importance of this to potential vaccine design is briefly discussed. 10 mi-sodium pyruvate (Gibco), 1 mi-oxaloacetic acid (Sigma), 0.2 units/ml bovine insulin (Sigma), 5 x 10 -s M-2-mercaptoethanol, 15 international units/ml recombinant human interleukin 2 (kind gift of Cetus Corporation) and 2~ (v/v) concanavalin A-derived rat T cell growth factor (with 25 mi-ct methylmannoside) prepared as described previously (Von Boehmer et aL, 1979) .
After 7 days culture, individual wells were washed once and their contents were split into four equal replicates in V-bottomed microtitre plates. The lytic activity in each individual well was assessed by the addition of various 51Cr-labelled targets to each replicate for 4 h, and determined as described previously (Rouse et al., 1983) .
Lymphoproliferation. Draining lymph node cells were obtained from mice 14 days after HSV-1 immunization.
Five x l0 s cells were cultured with 5 × 105 X-irradiated syngeneic spleen cells infected with one of the u.v.-irradiated viruses (m.o.i. of 5 before inactivation) for 5 days in U-bottomed microtitre plates. All culturing was performed in the limiting dilution medium described above except that the 10~ foetal calf serum was replaced with 1 ~ syngeneic mouse serum (obtained from non-immune mice and heat-inactivated). On the last day of culture 0.5 ~tCi of [3H]thymidine (ICN Pharmaceuticals) was added to each well. The incorporation of the tritiated label into cellular DNA after the final 24 h incubation was determined by liquid scintillation counting and used as a measure of lymphocyte proliferation.
Antibody measurements. HSV-l-specific antibodies were measured with an indirect ELISA or a microneutralization assay as described previously .
Infectivity assays. The HSV-l-infected mouse pinnae were removed 3 days after virus inoculation and stored at -70 °C until required. Ear flaps were homogenized and their infectious virus titre determined in a microtitration assay on Vero cells as described previously .
Statistical analysis. The mean difference in footpad swelling between the virus-challenged footpads and the mock-challenged footpads were analysed by Student's t-test. Calculation of CTL precursor frequencies (F) by limiting dilution analysis was performed by chi-squared minimization as described by Taswell (1981) . This analysis yielded the frequencies and their 95 ~ confidence limits, and the probability of single-hit kinetics. All other analyses were performed with Student's t-test.
RESULTS

Components of the immune response which recognize HSV-1 gB
The recombinant vaccinia virus VgB 11 has been demonstrated to produce a glycosylated cell surface molecule in infected cells which was indistinguishable from the authentic gB of HSV-1 strain F (Cantin et al., 1987) . We were also able to use Western blot analysis to show that murine cells infected with VgB11 produced serologically detectable gB at the cell surface and in cell extracts (data not shown).
To search for T cell recognition of VgB11-infected cells, a number of approaches were used. Thus, VgB11 was able to elicit a specific DTH response in HSV-l-immunized animals, an effect attributed to the recombinant gB gene since such DTH responses were not elicited by control vaccinia viruses (Table 1) . As a further measure of T cell recognition of gB, lymphoid cells from HSV-l-immunized mice were tested for proliferative and cytotoxic activity against VgBllinfected cells. Although gB-specific proliferative responses occurred (Table 1) , gB-specific CTL Were not demonstrable. This was the finding when populations of HSV-l-specific CTL from either H-2 b, H-2 d or H-2 k major histocompatibility complex (MHC) haplotype mice were i" The effector: target cell ratio was 50 : 1. Autologous L929 (H-2 k) and MHC mismatched allogeneic A31 (H-2 d) cells were used as targets for C3H CTLs, autologous EMT-6 (H-2 d) and MHC mismatched allogeneic L929 (H-2 k) cells were targets for BALB/c CTLs; autologous C57SV40 (H-2 b) and allogeneic control cells L929 (H-2 k) were targets for C57BL/6 CTLs.
:~ Mean ~ specific lysis of four replicate cultures + 1 S.D. § Significant lysis compared with mock-infected L cells.
analysed (Table 2) , or when HSV-l-immune splenocyte CTLs were expanded in vitro with HSV-1 to generate a memory CTL response (data not shown). This failure to detect a gB-specific CTL response in HSV-l-immune mice is in disagreement with the studies of Blacklaws et al. (1987) and McLaughlin-Taylor et al. (1988) . The former authors demonstrated a minor population of HSV-l-specific CTLs from CBA mice (H-2 k) which lysed autologous L cells expressing the HSV-1 KOS gB gene, whereas McLaughlin-Taylor et al. (1988) reported a population of CTLs specific for the HSV-1 F gB molecule demonstrable in BALB/c (H-2 d) mice. We addressed these discrepancies by using the combined techniques of limiting dilution culture and split well analysis to determine the recognition of VgB11-infected cells by HSV-l-specific CTLs at the clonal level. The data in Fig. 1 demonstrate that an acute HSV-1 CTL population, even with a high probability of being polyclonal (15 000 cells/well) whilst efficiently lysing histocompatible HSV-l-infected cells (F = 1/11280, range 1/9661 to 1/13551 for C3H mice and F = 1/8313, range 1/8056 to 1/8579 for BALB/c mice) failed to recognize VgB11-infected cells specifically. These data and those obtained from similar replicate experiments indicate that less than 2 ~ of HSV-l-specific CTLs recognize gB as their target antigen in the context of H-2 k or H-2 d MHC antigens. Curiously in these experiments up to 10~o of the HSV-l-specific CTLs generated in C3H (H-2 k) mice lysed HSV-l-infected MHC mismatched KD2 (H-2 o) target cells. Split well analysis of cultures with a high probability of being monoclonal indicated that these lytic cells are mostly specific for the allogeneic target [i.e. fail to lyse HSV-l-infected L (H-2 k) cells] and may be analogous to the population of H-2Kd-specific CTLs in HSV-l-immune lymphocytes reported previously (Pfizenmaier et al., 1980) .
Induction of anti-HSV-1 immune responses detected in vitro after immunization with VgBl l
Immunization of different strains of mice with the recombinant vaccinia virus VgBll induced significant titres of HSV-1-specific antibodies as measured by indirect ELISA (data not shown). Analysis of sera from individual mice for HSV-l-specific virus-neutralizing antibodies revealed that VgB 11 was a poor inducer of C'-dependent HSV-1 neutralizing antibodies, when compared to HSV-1 (Table 3) .
In agreement with previous reports which demonstrate induction of antiviral DTH responses after immunization with immunopurified preparations of gB (Chan et al., 1985) or L cells expressing gB (Blacklaws et al,, 1987) , immunization with VgB 11 provided a potent induction of HSV-l-specific DTH responses (Table 3) . However, VgB11 failed to induce a detectable anti-HSV-1 CTL response in C3H mice (Table 4) , or BALB/c and C57BL/6 mice despite its ability to induce both HSV-l-specific lymphoproliferation (data not shown) and a vaccinia virus-specific Table 4 demonstrate a weak vaccinia virus-specific CTL response in the splenocyte population obtained from either Vtk-or VgB11-immunized mice. Since this response is not usually seen in cultured lymphocytes obtained from mice immunized more than a month previously (data not shown), it presumably represents the remnants of a waning acute anti-vaccinia virus CTL response. 
TCIDso of
Induction of anti-HSV-1 immunity in vitro after immunization with VgBl l
As reported previously for immunization with VgD52 or affinitypurified gB (Chan et al., 1985) , vaccination of C3H/HeN mice with VgB11 induced a population of CD4 +, CD8-T lymphocytes which when adoptively transferred to naive syngeneic recipient mice conferred protection against a local challenge with HSV-I KOS (Table 5 ). This was also seen with the BALB/c (H-2 d) strain of mouse (data not shown). Protection was demonstrated as the ability of VgB11-immune animals, but not those immune to VHA36 or Vtk-, to reduce the titres of a 4 log10 HSV-1 challenge in an ear flap to below the level of detection by 3 days postchallenge. Nevertheless, as we have noted previously for VgD52-immunized animals , immunization with VgB11 failed to confer protection against a higher, 6 log10 challenge dose of HSV-1 in any of the mouse strains tested ( Fig. 2 and 3 ). This deficiency in the immunity of recombinant vaccinia virus-immunized mice compared to the level of immunity seen in HSV-l-immune mice was not attributable simply to an inadequate dose or route of inoculation of the immunogen. Thus, as shown in Table 6 2.2, --, 1.5 0-9 10, 14, 11, 11 11.5 Anti-CD4 + C' 3.5, 3'61 3-3, 4.5 3.7 5, 4, 1, 4 3-5 VgBll C' -, -, -, <l.5 12, 20, 9, 12 13-3 Anti-CD8 + C' 1.5, 2.2, 0.9 10, 9, 10, 10 9-8 Anti-CD4 + C' 3.1, 4.0, 2"91 4.0 3.5 2, 4, 3, 3 3.0 VgD52 C' -, -, -, -<1.5 10, 14, 11, 11 11.5 Anti-CD8 + C' -, 1.5, --0-4 10, 12, 10, 12 11-0 Anti-CD4 + C' 2-9, 4.3, 3-11 2.9 3.3 4, 2, 5, 5 4.0 VHa36 C' 2.2, 3.5, 3.5, 2.2 2.9 5, 4, 4, 5 4.5 * After treatment with J1 ld. 2, antiserum and C', 1 × I07 to 2 × 107 donor cells were inoculated into groups of four C3H/HeN mice. Three days post-HSV-1 challenge the left pinnae were removed and their residual infectious virus titre was determined. t-, Undetectable (i.e. < 1.5 loglo virus).
viruses failed to confer complete protection against a high (6 loglo) challenge with HSV-1. Furthermore, even a simultaneous inoculation of mice with each vaccinia virus vector (in separate sites) failed to confer protection against a 6 log10 challenge with HSV-1 (Table 6) , despite the presence of both gB-and gD-specific antibodies detectable by ELISA (data not shown).
Other observations included the fact that intravenous inoculation of VgBll or VgD52 induced a state of split tolerance in which all the expected measurable aspects of HSV-1 immunity were present except for the DTH response which was specifically suppressed (Fig. 4) . However, interestingly VgBll but not VgD52 intravenously immunized mice were (1) i.v. 2.9, 1.7, 2.1, 1.5, -1. 6 (1) s.c. (1) s.c.
-, , 1.9, -, ND 0"5 VHa36 (1) i.v. 3.8, 2-2, 3-8, 2.9, 4.5 3.4 (1) s.c. 3-5, 2.3, 2.5, 2.5, 2.6 2-7 (3) s.c. + i.p. 3.6, 3-8, 2-9, 2.8, 3.5 3.3 6 log~0 HSV-1 challenge Individual mice
2.4 3.5 3.8, 3.3, 2.9 1.9 2.7 1.9, 2.2, NDJI 2.9 3.3 -, 1.5, 1.9 1-9 1,9 2.5, 2.5, 1-9 2.9. 3.1 2-5, 2-5, 1-7 2.1, -, 2.2 1.9. 2.05, 1.7, 3.3, 3.7, 3'3, 3 .7 4.6 2.9 , 2.6, 3-6, 3. Fig. 4 . Suppression of HSV-l-specific DTH by intravenous injection of either VgB11, VgD52 or HSV-1. Groups of C3H/HeN mice were immunized by intravenous inoculation of the respective virus and 14 days later given a subcutaneous immunization of HSV-I into the left pinna. After a further 14 days animals were assessed for an HSV-l-specific DTH response using the footpad swelling response. Data are expressed as the mean footpad swelling of five mice + 1 S.D. Asterisks show significant reduction in the DTH response compared to the HSV-l-positive control.
Immunity to recombinant H S V -I glycoproteins
compromised in their ability to clear even a 4 IOglo challenge of HSV-1. This suggested that VgB11 induced a protective response which is attributable, at least partially, to the induction of an HSV-l-specific DTH response (Table 6 ).
DISCUSSION
Recombinant vaccinia viruses containing coding sequences for the genes of other viruses provide a valuable means of assessing the role of individual viral gene products at inducing immunity. We have used the recombinant vaccinia virus strategy primarily to evaluate the nature of the immune response to gB, one of seven or more major envelope glycoproteins of HSV (Spear, 1985) . Our results show that humoral immunity together with several, but not all, aspects of T ceU immunity are induced by VgB11. As with previous studies with recombinant vaccinia virus expressing the cloned gD gene of HSV , we failed to detect CD8 + class I MHC-restricted CTL induction, at least in mice with the MHC haplotype H-2 k, H-2 d or H-2 b. Moreover, as with gD, target cells infected with VgB11 and shown to express gB failed to act as targets for populations of HSV-specific CTL, even when analysed at the clonal level. Thus in these mouse strains, two major HSV envelope glycoproteins appear not to possess epitopes recognizable by or that can induce CTL, at least as analysed by means of the recombinant vaccinia virus approach. Currently, we lack a definitive explanation for our failure to demonstrate gB-specific CTL and our results with C3H mice contrast with reports of positive responses in CBA mice (H-2 k) using L cell targets transfected with the cloned gB gene and of McLaughlin-Taylor et al. (1988) who used the same vaccinia virus construct to induce HSV-1-specific CTL in BALB/c (H-2 o) mice.
Our failure to demonstrate class 1-restricted CTL responses to two major HSV glycoproteins in C3H mice is curious and did not apply to class II-restricted T cell recognition and induction where multiple parameters were demonstrated. These included helper cell induction, DTH, lymphoproliferation and, in the case of gD, class II-restricted CTL recognition . Moreover, both with gB (S. Martin et al., unpublished data) and gD , some aspects of CD8 + activity were induced. These could be detected by lymphoproliferation and suppressor cell assays. Accordingly, it remains difficult to explain a selective absence of CD8 ÷ class I-restricted recognition or induction. One possible explanation is that the VgB11 target system failed because insufficient processed gB molecules were able to compete with the myriad of processed vaccinia virus proteins also present in the infected cell for the available binding site on class I MHC molecules. Alternatively, because the gB sequences of the KOS and F strains of HSV-1 differ in a linear region of 12 amino acids (Bzik et al., 1984; Pellett et al., 1985) , it is possible that the epitope recognized by the HSV-1 F-specific CTL in the report of s. MARTIN, E. CANTIN AND B. T. ROUSE McLaughlin-Taylor et al. (1988) is not detected by the HSV-1 KOS-specific CTL we describe in this study.
As noted previously , following immunization with VgD52, levels of immunity induced by VgBll were significantly less than those that occurred after HSV immunization. To show this, we employed a model system of rapid viral clearance from the infected pinnae since others have judged this approach to be a better mimic of the pathogenesis of epithelial infection in man than is protection from lethal systemic disease often used to evaluate immunity (Hill et al., 1975) . Using the ear clearance system, mice immunized with HSV were able to clear an at least 100-fold higher challenge dose of virus than were VgB11-or VgD52-immunized mice. Since the major difference in the type of immune response induced was the lack of CTL induction, it is tempting to assume that this accounted for the suboptimal protective immune response. However, other explanations are possible such as a lower level of induction of those HSV-l-specific responses which are elicited by the recombinant virus. This explanation was considered unlikely because even in mice repeatedly immunized with the recombinant virus and in which easily quantifiable responses such as antibody were enhanced, mice still were unable to clear the high dose viral challenge. Another explanation for the suboptimal immunity induced by VgB11 and VgD52 could be because responses to more than one protein may be necessary for optimal clearance of virus. To approach this question, mice were immunized simultaneously with both VgB11 and VgD52 but levels of immunity induced were not elevated beyond those induced by either recombinant alone.
Although our results indicate that VgB 11 and VgD52 induce a lower level of protection than HSV, many aspects of resistance were induced and one or more of these was adequate to clear the lower challenge dose of virus. Our present studies cannot identify directly whether this clearance of low dose virus was mediated by humoral immunity or some property of CD4 + T cells. On the basis of adoptive transfer approaches used in previous studies, we had suggested that humoral immunity induced by VgD52 was responsible for the low dose viral clearance . In contrast, in the case of immunity induced by VgBll, humoral antibody may not provide a virus clearance mechanism. Accordingly, when VgBll was administered to mice via the intravenous route, a state of split tolerance was induced in which aspects of humoral immunity were unchanged but the DTH response was markedly suppressed. Unlike the situation with mice similarly made tolerant to VgD52 , those DTH tolerant to VgB 11 were unable to clear even the low dose challenge virus adequately. This indicates that immunity induced by VgBll is partly mediated by the DTH response.
In conclusion, our results demonstrate that for optimal levels of immunity against epithelial infection, multiple aspects of the immune response are necessary and that immunization with recombinant vaccinia viruses containing the cloned genes for at least two of the major surface glycoproteins elicit unsatisfactory levels of protection. This situation of suboptimal immunity induced by recombinant vaccinia viruses with HSV glycoprotein genes resembles many studies in which vaccination of animals with purified glycoprotein preparations, although inducing a protective response with respect to lethal challenge, usually failed to induce sufficient immunity to protect against HSV-1 replication in the epithelium (Berman et al., 1985; Stanberry et al., 1987; Meignier et al., 1987) . Consequently latency and concomitant recrudescence was rarely prevented.
Although our results provide no formal proof, they imply that suboptimal immunity results from a failure to induce the CTL response. Clearly we need to investigate recombinant vaccinia viruses containing HSV cloned genes which do induce a potent CTL response in an appropriate mouse strain. Since HSV codes for 60 or more proteins, there are many candidates for study other than the seven or so glycoproteins. However, we have recently constructed a recombinant vaccinia virus that expresses gC which is both capable of inducing HSV-specific CTL and eliciting immunity to high dose viral challenge in C3H mice (S. Martin et al., unpublished data) . Furthermore, from the observations on murine cytomegalovirus by Koszinowski's group (Jonjic et al., 1988) , and from our own studies on HSV (Martin et al., 1988) , we suspect that one or more of the immediate early proteins may act as a principal inducer of the CTL response. We are currently pursuing such studies in our laboratory.
